Addiction to apomorphine: a clinical case‐centred discussion
ABSTRACT Aim To report the case of a patient, who in the context of an anti‐Parkinsonian therapy, developed addiction to apomorphine. Methods Clinical case description. Results Apomorphine is a dopaminergic agonist that acts directly on D2 receptors. It has been used in alcoholism, male sexual dy...
Gespeichert in:
| Veröffentlicht in: | Addiction (Abingdon, England) England), 2006-11, Vol.101 (11), p.1662-1665 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1665 |
|---|---|
| container_issue | 11 |
| container_start_page | 1662 |
| container_title | Addiction (Abingdon, England) |
| container_volume | 101 |
| creator | Téllez, Carlos Bustamante, M. Leonor Toro, Pablo Venegas, Pablo |
| description | ABSTRACT
Aim To report the case of a patient, who in the context of an anti‐Parkinsonian therapy, developed addiction to apomorphine.
Methods Clinical case description.
Results Apomorphine is a dopaminergic agonist that acts directly on D2 receptors. It has been used in alcoholism, male sexual dysfunction and with diagnostic and therapeutic purposes in Parkinson’s disease (PD).
Conclusions The present work describes the case of a woman with PD who developed a loss of control over the consumption of apomorphine that resulted in a significant impairment of her functioning. PD patients with high frequency develop different psychiatric symptoms. Conversely, anti‐Parkinsonian drugs also generate psychiatric symptoms that can be experienced by the patient as pleasant sensations (‘alerting’, ‘awakening’, ‘activating’, hypomania and hypersexuality). In spite of this, addiction to these drugs in patients with PD is a very rare phenomenon. Currently, the prescription of apomorphine has been extended to patients with erectile dysfunction, which may increase the prevalence of addiction cases or of severe psychiatric symptoms. |
| doi_str_mv | 10.1111/j.1360-0443.2006.01580.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_57219204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>57219204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4780-13dcbd334c80a9c7e81c126f9af420c81382438135cc25578d4c10bd4cb28fa3</originalsourceid><addsrcrecordid>eNqNkN1KwzAYhoMobk5vQXqiZ61ffrqkgsLY_IOBJzsP6dcUM7p2NhtuZ16C1-iVmLrhTs1BvkCeN3l5CIkoJDSsm3lC-RBiEIInDGCYAE0VJJsj0v-7OCZ9yIZpzKiAHjnzfg4AUmXilPSoBC6EkH1yPyoKhyvX1NGqicyyWTTt8s3V9jYyEVaudmiqCI23359faOtVa4uocB7X3ofQOTkpTeXtxX4OyOzxYTZ-jqevTy_j0TRGIRXElBeYF5wLVGAylFZRpGxYZqYUDFBRrpjgYaSILE2lKgRSyMOeM1UaPiDXu2eXbfO-tn6lF6GCrSpT22btdSoZzRiIAKodiG3jfWtLvWzdwrRbTUF36vRcd4Z0Z0h36vSvOr0J0cv9H-t8YYtDcO8qAFd7wPggpWxNjc4fOEWlDBUCd7fjPlxlt_8uoEeTSXfiP-AjiXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>57219204</pqid></control><display><type>article</type><title>Addiction to apomorphine: a clinical case‐centred discussion</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Téllez, Carlos ; Bustamante, M. Leonor ; Toro, Pablo ; Venegas, Pablo</creator><creatorcontrib>Téllez, Carlos ; Bustamante, M. Leonor ; Toro, Pablo ; Venegas, Pablo</creatorcontrib><description>ABSTRACT
Aim To report the case of a patient, who in the context of an anti‐Parkinsonian therapy, developed addiction to apomorphine.
Methods Clinical case description.
Results Apomorphine is a dopaminergic agonist that acts directly on D2 receptors. It has been used in alcoholism, male sexual dysfunction and with diagnostic and therapeutic purposes in Parkinson’s disease (PD).
Conclusions The present work describes the case of a woman with PD who developed a loss of control over the consumption of apomorphine that resulted in a significant impairment of her functioning. PD patients with high frequency develop different psychiatric symptoms. Conversely, anti‐Parkinsonian drugs also generate psychiatric symptoms that can be experienced by the patient as pleasant sensations (‘alerting’, ‘awakening’, ‘activating’, hypomania and hypersexuality). In spite of this, addiction to these drugs in patients with PD is a very rare phenomenon. Currently, the prescription of apomorphine has been extended to patients with erectile dysfunction, which may increase the prevalence of addiction cases or of severe psychiatric symptoms.</description><identifier>ISSN: 0965-2140</identifier><identifier>EISSN: 1360-0443</identifier><identifier>DOI: 10.1111/j.1360-0443.2006.01580.x</identifier><identifier>PMID: 17034447</identifier><identifier>CODEN: ADICE5</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Addiction ; Addictive behaviors ; Adult and adolescent clinical studies ; Antiparkinson Agents - administration & dosage ; anti‐Parkinsonian drugs ; apomorphine ; Apomorphine - administration & dosage ; Apomorphine test ; Biological and medical sciences ; Dopamine Agonists - administration & dosage ; Drug addiction ; Drugs ; Female ; Humans ; Medical sciences ; Middle Aged ; Morphine Dependence - etiology ; Parkinson Disease - drug therapy ; Parkinson's disease ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Toxicology</subject><ispartof>Addiction (Abingdon, England), 2006-11, Vol.101 (11), p.1662-1665</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4780-13dcbd334c80a9c7e81c126f9af420c81382438135cc25578d4c10bd4cb28fa3</citedby><cites>FETCH-LOGICAL-c4780-13dcbd334c80a9c7e81c126f9af420c81382438135cc25578d4c10bd4cb28fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1360-0443.2006.01580.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1360-0443.2006.01580.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,30998,45572,45573</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18177043$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17034447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Téllez, Carlos</creatorcontrib><creatorcontrib>Bustamante, M. Leonor</creatorcontrib><creatorcontrib>Toro, Pablo</creatorcontrib><creatorcontrib>Venegas, Pablo</creatorcontrib><title>Addiction to apomorphine: a clinical case‐centred discussion</title><title>Addiction (Abingdon, England)</title><addtitle>Addiction</addtitle><description>ABSTRACT
Aim To report the case of a patient, who in the context of an anti‐Parkinsonian therapy, developed addiction to apomorphine.
Methods Clinical case description.
Results Apomorphine is a dopaminergic agonist that acts directly on D2 receptors. It has been used in alcoholism, male sexual dysfunction and with diagnostic and therapeutic purposes in Parkinson’s disease (PD).
Conclusions The present work describes the case of a woman with PD who developed a loss of control over the consumption of apomorphine that resulted in a significant impairment of her functioning. PD patients with high frequency develop different psychiatric symptoms. Conversely, anti‐Parkinsonian drugs also generate psychiatric symptoms that can be experienced by the patient as pleasant sensations (‘alerting’, ‘awakening’, ‘activating’, hypomania and hypersexuality). In spite of this, addiction to these drugs in patients with PD is a very rare phenomenon. Currently, the prescription of apomorphine has been extended to patients with erectile dysfunction, which may increase the prevalence of addiction cases or of severe psychiatric symptoms.</description><subject>Addiction</subject><subject>Addictive behaviors</subject><subject>Adult and adolescent clinical studies</subject><subject>Antiparkinson Agents - administration & dosage</subject><subject>anti‐Parkinsonian drugs</subject><subject>apomorphine</subject><subject>Apomorphine - administration & dosage</subject><subject>Apomorphine test</subject><subject>Biological and medical sciences</subject><subject>Dopamine Agonists - administration & dosage</subject><subject>Drug addiction</subject><subject>Drugs</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morphine Dependence - etiology</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Toxicology</subject><issn>0965-2140</issn><issn>1360-0443</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkN1KwzAYhoMobk5vQXqiZ61ffrqkgsLY_IOBJzsP6dcUM7p2NhtuZ16C1-iVmLrhTs1BvkCeN3l5CIkoJDSsm3lC-RBiEIInDGCYAE0VJJsj0v-7OCZ9yIZpzKiAHjnzfg4AUmXilPSoBC6EkH1yPyoKhyvX1NGqicyyWTTt8s3V9jYyEVaudmiqCI23359faOtVa4uocB7X3ofQOTkpTeXtxX4OyOzxYTZ-jqevTy_j0TRGIRXElBeYF5wLVGAylFZRpGxYZqYUDFBRrpjgYaSILE2lKgRSyMOeM1UaPiDXu2eXbfO-tn6lF6GCrSpT22btdSoZzRiIAKodiG3jfWtLvWzdwrRbTUF36vRcd4Z0Z0h36vSvOr0J0cv9H-t8YYtDcO8qAFd7wPggpWxNjc4fOEWlDBUCd7fjPlxlt_8uoEeTSXfiP-AjiXw</recordid><startdate>200611</startdate><enddate>200611</enddate><creator>Téllez, Carlos</creator><creator>Bustamante, M. Leonor</creator><creator>Toro, Pablo</creator><creator>Venegas, Pablo</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>200611</creationdate><title>Addiction to apomorphine: a clinical case‐centred discussion</title><author>Téllez, Carlos ; Bustamante, M. Leonor ; Toro, Pablo ; Venegas, Pablo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4780-13dcbd334c80a9c7e81c126f9af420c81382438135cc25578d4c10bd4cb28fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Addiction</topic><topic>Addictive behaviors</topic><topic>Adult and adolescent clinical studies</topic><topic>Antiparkinson Agents - administration & dosage</topic><topic>anti‐Parkinsonian drugs</topic><topic>apomorphine</topic><topic>Apomorphine - administration & dosage</topic><topic>Apomorphine test</topic><topic>Biological and medical sciences</topic><topic>Dopamine Agonists - administration & dosage</topic><topic>Drug addiction</topic><topic>Drugs</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morphine Dependence - etiology</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Téllez, Carlos</creatorcontrib><creatorcontrib>Bustamante, M. Leonor</creatorcontrib><creatorcontrib>Toro, Pablo</creatorcontrib><creatorcontrib>Venegas, Pablo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><jtitle>Addiction (Abingdon, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Téllez, Carlos</au><au>Bustamante, M. Leonor</au><au>Toro, Pablo</au><au>Venegas, Pablo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addiction to apomorphine: a clinical case‐centred discussion</atitle><jtitle>Addiction (Abingdon, England)</jtitle><addtitle>Addiction</addtitle><date>2006-11</date><risdate>2006</risdate><volume>101</volume><issue>11</issue><spage>1662</spage><epage>1665</epage><pages>1662-1665</pages><issn>0965-2140</issn><eissn>1360-0443</eissn><coden>ADICE5</coden><abstract>ABSTRACT
Aim To report the case of a patient, who in the context of an anti‐Parkinsonian therapy, developed addiction to apomorphine.
Methods Clinical case description.
Results Apomorphine is a dopaminergic agonist that acts directly on D2 receptors. It has been used in alcoholism, male sexual dysfunction and with diagnostic and therapeutic purposes in Parkinson’s disease (PD).
Conclusions The present work describes the case of a woman with PD who developed a loss of control over the consumption of apomorphine that resulted in a significant impairment of her functioning. PD patients with high frequency develop different psychiatric symptoms. Conversely, anti‐Parkinsonian drugs also generate psychiatric symptoms that can be experienced by the patient as pleasant sensations (‘alerting’, ‘awakening’, ‘activating’, hypomania and hypersexuality). In spite of this, addiction to these drugs in patients with PD is a very rare phenomenon. Currently, the prescription of apomorphine has been extended to patients with erectile dysfunction, which may increase the prevalence of addiction cases or of severe psychiatric symptoms.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17034447</pmid><doi>10.1111/j.1360-0443.2006.01580.x</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0965-2140 |
| ispartof | Addiction (Abingdon, England), 2006-11, Vol.101 (11), p.1662-1665 |
| issn | 0965-2140 1360-0443 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_57219204 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA) |
| subjects | Addiction Addictive behaviors Adult and adolescent clinical studies Antiparkinson Agents - administration & dosage anti‐Parkinsonian drugs apomorphine Apomorphine - administration & dosage Apomorphine test Biological and medical sciences Dopamine Agonists - administration & dosage Drug addiction Drugs Female Humans Medical sciences Middle Aged Morphine Dependence - etiology Parkinson Disease - drug therapy Parkinson's disease Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Toxicology |
| title | Addiction to apomorphine: a clinical case‐centred discussion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T06%3A16%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addiction%20to%20apomorphine:%20a%20clinical%20case%E2%80%90centred%20discussion&rft.jtitle=Addiction%20(Abingdon,%20England)&rft.au=T%C3%A9llez,%20Carlos&rft.date=2006-11&rft.volume=101&rft.issue=11&rft.spage=1662&rft.epage=1665&rft.pages=1662-1665&rft.issn=0965-2140&rft.eissn=1360-0443&rft.coden=ADICE5&rft_id=info:doi/10.1111/j.1360-0443.2006.01580.x&rft_dat=%3Cproquest_cross%3E57219204%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=57219204&rft_id=info:pmid/17034447&rfr_iscdi=true |